The Outcome of Patients with Cerebral Arteriovenous Malformations (AVMs) Treated with Stereotactic Radiosurgery (SRS) Using the CyberKnife (Rationale, Benefits and Risks): A Real-World Experience | ||||
Research in Oncology | ||||
Articles in Press, Corrected Proof, Available Online from 30 March 2024 PDF (215.94 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/resoncol.2024.258069.1204 | ||||
View on SCiNiTO | ||||
Authors | ||||
Ahmed A. Awad1, 2; Ameen S. Alomair1; Mohammed M. Rizwanullah1; Adnan S. Alhebshi3; Amr Taha 4, 2; Faisal S. Alzorkany5; Mohammed A. Alkafi5; Joti Phattacharya6; Ahmed M. Elashwah 1, 7 | ||||
1Section of Radiation Oncology, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia | ||||
2Radiation Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt | ||||
3Radiation Oncology Department, Johns Hopkins Aramco Health Care, Dhahran, Saudi Arabia | ||||
4Radiation Oncology Department, King Fahad Specialist Hospital, Buraydah, Saudi Arabia | ||||
5Biomedical Physics Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia | ||||
6Intervention Radiology Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia | ||||
7Department of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt | ||||
Abstract | ||||
Background: Cerebral arteriovenous malformations (AVMs) are complex, heterogeneous, uncommon lesions that carry a high risk of intracranial hemorrhage with subsequent disability. Aim: To evaluate the outcome of patients with cerebral AVMs treated in our center, King Faisal Specialized Hospital and Research Center (KFSH&RC) Saudi Arabia with SRS using the CyberKnife. Methods: Medical records of patients treated in the above-mentioned way in the period between 2009-2021 were retrospectively evaluated. Results: A total of 51 patients were included in this study. The median age at diagnosis was 31 (3-77) years. Neurological alteration and intracranial hemorrhage were the most common presentations in 24 (47.1%) patients. The mean maximum AVM nidus diameter and volume were 2.9 cm and 5.9 cc respectively. All the patients received SRS using CyberKnife with a median marginal dose of 20 (14-21) Gy over a single fraction. Volume staged treatment was applied in 4 (7.8%) patients. After a median follow-up of 37 (2-170) months, all patients were alive with successful obliteration of the AVM nidus occurring in 31 (60.8%) patients after a median latency period of 27 (4-68.9) months in those who achieved complete obliteration. No patients developed post-SRS hemorrhage and 11 (21.6%) patients developed post-SRS radiological radiation-induced changes of which only 3 (27.3%) patients were symptomatic (in the form of uncontrolled seizures). only SRS dose > 19 Gy was significantly correlated with the obliteration rate, as 79.3% of patients who received SRS dose > 19 Gy achieved obliteration vs 36.4 % only in those who received dose Conclusion: SRS treatment using CyberKnife is effective management for patients with cerebral AVMs without an increase in the incidence of post-SRS hemorrhage, stroke, or death. | ||||
Keywords | ||||
Arteriovenous malformations; CyberKnife; Stereotactic radiosurgery | ||||
Statistics Article View: 50 PDF Download: 37 |
||||